Skip to content

Author

Wafa Ali Asaad

We have 1 of 10 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Baseline ECOG Performance Status 0 Versus 1 as a Modifier of Treatment Benefit from Adding an Immune Checkpoint Inhibitor to Chemotherapy: A Systematic Review and Meta-Analysis.

BACKGROUND Immune checkpoint inhibitors (ICIs) added to chemotherapy are established in solid tumors, but most trials enroll patients with ECOG performance status (PS) 0-1 patients. Whether baseline PS modifies the relative benefit of adding an ICI has not been formally tested using a within-trial interaction analysis....

Wafa Ali Asaad, Salah Ameen Abdu, Yue-Ying Zhou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.